dihexa fda approval status Peptide Therapy: Brain & Memory Support FDA Peptide Update: Category 2
Description
In both age cohorts, mRNA-1083 generated statistically significantly higher immune responses against three influenza virus strains (H1N1, H3N2, and B/Victoria) and against the Omicron variant of SARS-CoV-2

So happy with this product so far
Mol Cancer

2023;186(2):382-97.e24